Tag: Yeztugo

In June 2025, the FDA approved Yeztugo (lenacapavir), the first and only twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP). For individuals considering this innovative treatment, the pressing question is, "Will insurance cover Yeztugo?".

Lenacapavir is a first-in-class HIV capsid inhibitor that can be dosed twice-yearly, marking a significant advancement in the treatment and prevention of HIV. Knowing what is another name for lenacapavir, specifically its brand names, is important as they indicate the medication's intended use.

Following two separate FDA approvals, **is lenacapavir available in the US** for both the treatment of multi-drug resistant HIV and for HIV prevention (PrEP). The latter, approved in June 2025, represents a significant step forward with its injectable administration, offering a novel, long-acting option for eligible individuals.

Lenacapavir is a first-in-class, long-acting HIV capsid inhibitor administered as a twice-yearly injection, a significant advancement in HIV care. Understanding who qualifies for lenacapavir is crucial, as eligibility depends on its intended use for either prevention (PrEP) or treating multi-drug resistant HIV.

Named the "Breakthrough of the Year" by *Science* magazine in 2024, lenacapavir is a first-in-class, long-acting medication used for both the treatment of multi-drug resistant HIV and for pre-exposure prophylaxis (PrEP). It is a capsid inhibitor that acts on the virus in multiple stages of its lifecycle, a novel approach compared to older antiretroviral therapies.

In June 2025, the U.S. Food and Drug Administration (FDA) approved Yeztugo (lenacapavir) as the first and only twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP). The mechanism of action of Yeztugo involves targeting the viral capsid at multiple points in the HIV-1 life cycle.

In recent clinical trials, lenacapavir demonstrated a 96% lower incidence of HIV infection compared to background incidence for prevention. This incredible efficacy stems from the fact that lenacapavir is a first-in-class, long-acting HIV-1 capsid inhibitor, offering a groundbreaking new approach to managing and preventing HIV.